12 assets in Glycogen Storage Disease Due To Acid Maltase Deficiency, Late-Onset

Therapeutic assets addressing Glycogen Storage Disease Due To Acid Maltase Deficiency, Late-Onset, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Alglucosidase Alfa Glycogen Storage Disease Due To Acid Maltase Deficiency, Late-Onset	Erasmus Medical Center	P4	BBB (78)
Cipaglucosidase Alfa Glycogen Storage Disease Due To Acid Maltase Deficiency, Late-Onset	Amicus Therapeutics	P3	BB (66)
Avalglucosidase Alfa Glycogen Storage Disease Due To Acid Maltase Deficiency, Late-Onset	Iris Plug	P4	BB (65)
Miglustat Glycogen Storage Disease Due To Acid Maltase Deficiency, Late-Onset	Amicus Therapeutics	P3	B (62)
Clenbuterol Glycogen Storage Disease Due To Acid Maltase Deficiency, Late-Onset	Duke University	P2	CCC (53)
ab-1009 Glycogen Storage Disease Due To Acid Maltase Deficiency, Late-Onset	AskBio Inc	P1/2	CC (47)
AT845 Glycogen Storage Disease Due To Acid Maltase Deficiency, Late-Onset	Astellas Gene Therapies	P1/2	CC (47)
Dna (Recombinant Adeno-Associated Virus Vector Aav-Spark100-Gaa Human Liver-Specific Expression Cassette Including Human Lysosomal ?-Glucosidase Codon-Optimized Gene Gaa Plus Adeno-Associated Virus 2 Inverted Terminal Repeat Flanks) Glycogen Storage Disease Due To Acid Maltase Deficiency, Late-Onset	Spark Therapeutics, Inc.	P1/2	CC (47)
gc301 Glycogen Storage Disease Due To Acid Maltase Deficiency, Late-Onset	GeneCradle Inc	P1/2	CC (47)
dnl952 Glycogen Storage Disease Due To Acid Maltase Deficiency, Late-Onset	Denali Therapeutics Inc.	P1	CC (43)
ABX1100 Glycogen Storage Disease Due To Acid Maltase Deficiency, Late-Onset	Aro Biotherapeutics	Early P1	NR ()
crg003 Glycogen Storage Disease Due To Acid Maltase Deficiency, Late-Onset	Huashan Hospital	Early P1	NR ()